Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
Chinese official says US tariff aims to 'take away Hong Kong's life'
15/04/2025
HDFC Defence Fund hikes stake in BEML & Solar Industries, adds Centum Electronics in March
15/04/2025
Technical picks : NTPC, Bharti Hexacom among 4 stocks to buy for up to 34% returns in short term
15/04/2025
Technical picks : NTPC, Bharti Hexacom among 4 stocks to buy for up to 34% returns in short term
15/04/2025
ETMarkets Smart Talk | IT, Pharma face global headwinds ; Banks and Telcos offer safety : BNP Paribas’ Abhiram Eleswarapu
15/04/2025
UBS lowers forecast for China 2025 GDP growth to 3.4% on tariff hikes
15/04/2025
